Interojo Inc. (KOSDAQ:119610)
17,620
-330 (-1.84%)
Jun 12, 2026, 3:30 PM KST
Interojo Revenue
Interojo had revenue of 30.72B KRW in the quarter ending March 31, 2026, with 32.82% growth. This brings the company's revenue in the last twelve months to 126.03B, up 19.65% year-over-year. In the year 2025, Interojo had annual revenue of 118.44B with 2.24% growth.
Revenue (ttm)
126.03B
Revenue Growth
+19.65%
P/S Ratio
1.60
Revenue / Employee
183.45M
Employees
687
Market Cap
201.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.44B | 2.60B | 2.24% |
| Dec 31, 2024 | 115.84B | -3.46B | -2.90% |
| Dec 31, 2023 | 119.30B | 1.48B | 1.25% |
| Dec 31, 2022 | 117.82B | 10.29B | 9.57% |
| Dec 31, 2021 | 107.53B | 19.33B | 21.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.81T |
| Celltrion | 4.47T |
| Samsung Epis Holdings | 1.51T |
| Chong Kun Dang Holdings | 952.66B |
| Suheung | 743.02B |
| Bioneer | 338.01B |
| Whan In Pharm | 266.19B |
| ALTEOGEN | 203.76B |